Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income margin | 17.9% | 37.0% | 18.2% | 3.0% | (29.1%) | 7.0% | 27.2% | 42.8% | 46.0% | 26.2% | 41.8% | 47.7% | 66.4% | 47.2% | 49.5% | (12.9%) | 40.0% | 33.0% | 50.6% | 50.9% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Operating Income margin is 46.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Operating Income margin for United Therapeutics Corporation have been 43.6% over the past three years, and 39.9% over the past five years.
As of today, United Therapeutics Corporation's Operating Income margin is 46.4%, which is higher than industry median of (916.0%). It indicates that United Therapeutics Corporation's Operating Income margin is Good.